Table of Contents 1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Overview 1.1 Product Overview and Scope of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs 1.2 Classification of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs by Types 1.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Comparison by Types (2019-2024) 1.2.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Types in 2018 1.2.3 Afinitor (Everolimus) 1.2.4 Avastin (Bevacizumab) 1.2.5 Cabomety (Cabozantinib) 1.2.6 Inlyta (Axitinib) 1.2.7 Nexavar (Sorafenib) 1.2.8 Proleukin (Aldesleukin) 1.2.9 Torisel (Temsirolimus) 1.2.10 Sutent (Sunitinib) 1.2.11 Votrient (Pazopanib) 1.3 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market by Application 1.3.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Market Share Comparison by Applications (2014-2024) 1.3.2 Hospitals 1.3.3 Clinic 1.3.4 Others 1.4 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market by Regions 1.4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (Million USD) Comparison by Regions (2014-2024) 1.4.1 North America (USA, Canada and Mexico) Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Status and Prospect (2014-2024) 1.4.2 Europe (Germany, France, UK, Russia and Italy) Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Status and Prospect (2014-2024) 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Status and Prospect (2014-2024) 1.4.4 South America (Brazil, Argentina, Colombia) Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Status and Prospect (2014-2024) 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Status and Prospect (2014-2024) 1.5 Global Market Size of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs (2014-2024) 2 Company Profiles 2.1 Novartis Ag 2.1.1 Business Overview 2.1.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications 2.1.2.1 Product A 2.1.2.2 Product B 2.1.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) 2.2 Pfizer, Inc.  2.2.1 Business Overview 2.2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications 2.2.2.1 Product A 2.2.2.2 Product B 2.2.3 Pfizer, Inc.  Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) 2.3 Cipla Limited 2.3.1 Business Overview 2.3.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications 2.3.2.1 Product A 2.3.2.2 Product B 2.3.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) 2.4 Amgen 2.4.1 Business Overview 2.4.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications 2.4.2.1 Product A 2.4.2.2 Product B 2.4.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) 2.5 Active Biotech Ab 2.5.1 Business Overview 2.5.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications 2.5.2.1 Product A 2.5.2.2 Product B 2.5.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) 2.6 Bayer AG 2.6.1 Business Overview 2.6.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications 2.6.2.1 Product A 2.6.2.2 Product B 2.6.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) 2.7 Glaxosmithkline Plc 2.7.1 Business Overview 2.7.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications 2.7.2.1 Product A 2.7.2.2 Product B 2.7.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) 2.8 Roche Holding AG 2.8.1 Business Overview 2.8.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications 2.8.2.1 Product A 2.8.2.2 Product B 2.8.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) 3 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Competition, by Players 3.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Share by Players (2014-2019) 3.2 Market Concentration Rate 3.2.1 Top 5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players Market Share 3.2.2 Top 10 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players Market Share 3.3 Market Competition Trend 4 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions 4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Market Share by Regions 4.2 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 4.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 4.4 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 4.5 South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 4.6 Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 5 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries 5.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries (2014-2019) 5.2 USA Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 5.3 Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 5.4 Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 6 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries 6.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries (2014-2019) 6.2 Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 6.3 UK Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 6.4 France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 6.5 Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 6.6 Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 7 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries 7.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries (2014-2019) 7.2 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 7.3 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 7.4 Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 7.5 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 7.6 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 8 South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries 8.1 South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries (2014-2019) 8.2 Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 8.3 Argentina Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 8.4 Colombia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 9 Middle East and Africa Revenue Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs by Countries 9.1 Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries (2014-2019) 9.2 Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 9.3 UAE Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 9.4 Egypt Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 9.5 Nigeria Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 9.6 South Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) 10 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment by Type 10.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Market Share by Type (2014-2019) 10.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Forecast by Type (2019-2024) 10.3 Afinitor (Everolimus) Revenue Growth Rate (2014-2024) 10.4 Avastin (Bevacizumab) Revenue Growth Rate (2014-2024) 10.5 Cabomety (Cabozantinib) Revenue Growth Rate (2014-2024) 10.6 Inlyta (Axitinib) Revenue Growth Rate (2014-2024) 10.7 Nexavar (Sorafenib) Revenue Growth Rate (2014-2024) 10.8 Proleukin (Aldesleukin) Revenue Growth Rate (2014-2024) 10.9 Torisel (Temsirolimus) Revenue Growth Rate (2014-2024) 10.10 Sutent (Sunitinib) Revenue Growth Rate (2014-2024) 10.11 Votrient (Pazopanib) Revenue Growth Rate (2014-2024) 11 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment by Application 11.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Application (2014-2019) 11.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Forecast by Application (2019-2024) 11.3 Hospitals Revenue Growth (2014-2019) 11.4 Clinic Revenue Growth (2014-2019) 11.5 Others Revenue Growth (2014-2019) 12 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Forecast (2019-2024) 12.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Forecast (2019-2024) 12.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Forecast by Regions (2019-2024) 12.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Forecast (2019-2024) 12.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Forecast (2019-2024) 12.5 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Forecast (2019-2024) 12.6 South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Forecast (2019-2024) 12.7 Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Forecast (2019-2024) 13 Research Findings and Conclusion 14 Appendix 14.1 Methodology 14.2 Data Source

List of Tables and Figures Figure Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Picture Table Product Specifications of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs and Revenue (Million USD) Market Split by Product Type Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Types in 2018 Figure Afinitor (Everolimus) Picture Figure Avastin (Bevacizumab) Picture Figure Cabomety (Cabozantinib) Picture Figure Inlyta (Axitinib) Picture Figure Nexavar (Sorafenib) Picture Figure Proleukin (Aldesleukin) Picture Figure Torisel (Temsirolimus) Picture Figure Sutent (Sunitinib) Picture Figure Votrient (Pazopanib) Picture Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) by Application (2014-2024) Figure Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Applications in 2018 Figure Hospitals Picture Figure Clinic Picture Figure Others Picture Table Global Market Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) Comparison by Regions 2014-2024 Figure North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) and Growth Rate (2014-2024) Figure Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) and Growth Rate (2014-2024) Figure Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) and Growth Rate (2014-2024) Figure South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) and Growth Rate (2014-2024) Figure Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) and Growth Rate (2014-2024) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) and Growth Rate (2014-2024) Table Novartis Ag Basic Information, Manufacturing Base and Competitors Table Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications Table Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) Table Pfizer, Inc.  Basic Information, Manufacturing Base and Competitors Table Pfizer, Inc.  Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications Table Pfizer, Inc.  Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) Table Cipla Limited Basic Information, Manufacturing Base and Competitors Table Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications Table Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) Table Amgen Basic Information, Manufacturing Base and Competitors Table Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications Table Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) Table Active Biotech Ab Basic Information, Manufacturing Base and Competitors Table Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications Table Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) Table Bayer AG Basic Information, Manufacturing Base and Competitors Table Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications Table Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) Table Glaxosmithkline Plc Basic Information, Manufacturing Base and Competitors Table Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications Table Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) Table Roche Holding AG Basic Information, Manufacturing Base and Competitors Table Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Type and Applications Table Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2017-2018) Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) by Players (2014-2019) Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Players (2014-2019) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Players in 2017 Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Players in 2018 Figure Global Top 5 Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share in 2018 Figure Global Top 10 Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share in 2018 Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) and Growth Rate (%) (2014-2019) Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) by Regions (2014-2019) Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Regions (2014-2019) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Regions (2014-2019) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Regions in 2018 Figure North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Table North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries (2014-2019) Table North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries (2014-2019) Figure North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries (2014-2019) Figure North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries in 2018 Figure USA Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Table Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) by Countries (2014-2019) Figure Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries (2014-2019) Figure Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries in 2018 Figure Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure UK Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Table Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) by Countries (2014-2019) Figure Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries (2014-2019) Figure Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries in 2018 Figure China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Table South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Countries (2014-2019) Table South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries (2014-2019) Figure South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries (2014-2019) Figure South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries in 2018 Figure Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Argentina Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Colombia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Table Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) by Countries (2014-2019) Table Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries (2014-2019) Figure Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries (2014-2019) Figure Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Countries in 2018 Figure Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure UAE Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Egypt Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure Nigeria Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Figure South Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Growth Rate (2014-2019) Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) by Type (2014-2019) Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Type (2014-2019) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Type (2014-2019) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Type in 2018 Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Forecast by Type (2019-2024) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share Forecast by Type (2019-2024) Figure Global Afinitor (Everolimus) Revenue Growth Rate (2014-2019) Figure Global Avastin (Bevacizumab) Revenue Growth Rate (2014-2019) Figure Global Cabomety (Cabozantinib) Revenue Growth Rate (2014-2019) Figure Global Inlyta (Axitinib) Revenue Growth Rate (2014-2019) Figure Global Nexavar (Sorafenib) Revenue Growth Rate (2014-2019) Figure Global Proleukin (Aldesleukin) Revenue Growth Rate (2014-2019) Figure Global Torisel (Temsirolimus) Revenue Growth Rate (2014-2019) Figure Global Sutent (Sunitinib) Revenue Growth Rate (2014-2019) Figure Global Votrient (Pazopanib) Revenue Growth Rate (2014-2019) Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Application (2014-2019) Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Application (2014-2019) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Application (2014-2019) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Application in 2018 Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Forecast by Application (2019-2024) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share Forecast by Application (2019-2024) Figure Global Hospitals Revenue Growth Rate (2014-2019) Figure Global Clinic Revenue Growth Rate (2014-2019) Figure Global Others Revenue Growth Rate (2014-2019) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) and Growth Rate Forecast (2019-2024) Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (Million USD) Forecast by Regions (2019-2024) Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share Forecast by Regions (2019-2024) Figure North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Forecast (2019-2024) Figure Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Forecast (2019-2024) Figure Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Forecast (2019-2024) Figure South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Forecast (2019-2024) Figure Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Forecast (2019-2024)

Cipla Limited Amgen Active Biotech Ab Roche Holding AG Bayer AG Pfizer, Inc.  Glaxosmithkline Plc Novartis Ag